HSP90AB1 and neoplasm: Inhibition of Hsp90 causes client protein degradation via the ubiquitin-proteasome pathway and is a mechanism that might simultaneously downregulate several redundant pathways crucial for cell viability and tumor development, which has resulted in substantial antitumor effects in preclinical models and could potentially prevent the emergence of tumor drug resistance.